Previous Close | 23.53 |
Open | 22.57 |
Bid | 23.60 |
Ask | 24.80 |
Strike | 120.00 |
Expire Date | 2024-06-21 |
Day's Range | 22.57 - 22.57 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024 — but the success comes with ongoing criticism about pricing and access.
These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.